MannKind Corporation (NASDAQ:MNKD) and One Drop announced the first step of their collaboration with the launch of the A-ONE study, a randomized controlled trial investigating the use of Afrezza® inhaled insulin and One Drop’s integrated digital diabetes care platform.

In May 2017, MannKind and One Drop announced a memorandum of understanding to explore collaborations related to One Drop | Premium (i.e., One Drop | Mobile app, One Drop | Chrome meter and test strips, One Drop | Experts coaching service) and Afrezza®, MannKind’s inhaled rapid-acting mealtime insulin. One goal of the collaboration is to identify ways of simplifying the complexity of starting and staying on mealtime insulin along with Customized Coaching to help people achieve their A1C goals.

Appropriate people with type 2 diabetes who meet inclusion criteria will be randomized to one of two treatment arms:  Afrezza® with One Drop | Premium — or — One Drop | Premium alone. Changes in hemoglobin A1C, quality of life, self-care, treatment satisfaction, and other metrics will be assessed.  People with type 2 diabetes interested in learning more should email Aone@onedrop.today.

Dr. Raymond Urbanski, Chief Medical Officer of MannKind Corporation, said, “This study is intended to evaluate whether combining a solutions-oriented digital disease management platform like One Drop with an innovative drug like Afrezza® will provide patients with an improved ability to manage their diabetes.”

“One Drop is a unique, fully integrated solution with the prospects of a huge health benefit,” says Dr. Chandra Osborn, VP of Health and Behavioral Informatics at One Drop. “We know each piece of the puzzle works, and now we want to see how well they work together. With 9 peer-reviewed outcomes shared at medical meetings and a paper in press at JMIR Diabetes, One Drop is committed to delivering the most effective diabetes management solution in the market. The combination of One Drop with inhaled insulin could offer consumers, health care providers, and payers a potentially powerful solution with unprecedented benefits.”

“Diabetes technology is evolving in a very exciting way,” said Jeff Dachis, CEO and Founder of One Drop. “But not surprisingly for the vast majority of people with diabetes worldwide, expensive sensors, automated insulin delivery solutions, or call center approaches to care can create barriers and challenges to effective disease management. However, we are excited to evaluate whether a completely integrated digital diabetes therapeutics platform — encompassing evidence-based interventions, ADA-recognized diabetes education and coaching, wireless blood glucose tracking, user-centered design, robust data science, and an innovative pharmaceutical product like MannKind’s Afrezza — can deliver improved health outcomes at a fraction of the cost of current standards of care.”

Shares of MannKind are currently trading at $1.18, down $0.04 or -3.28%. MNKD has a 1-year high of $5.05 and a 1-year low of $0.67. The stock’s 50-day moving average is $1.34 and its 200-day moving average is $1.22.

On the ratings front, MannKind has been the subject of a number of recent research reports. In a report issued on May 11, J.P. Morgan analyst Cory Kasimov reiterated a Sell rating on MNKD. Separately, on the same day, Piper Jaffray’s Joshua Schimmer reiterated a Sell rating on the stock and has a price target of $0.54.

According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Cory Kasimov and Joshua Schimmer have a yearly average return of 1.8% and 0.5% respectively. Kasimov has a success rate of 41% and is ranked #1838 out of 4628 analysts, while Schimmer has a success rate of 50% and is ranked #2353.

MannKind Corp. is a biopharmaceutical company. It focuses on the discovery, development and commercialization of therapeutic products for diseases, such as diabetes and cancer.